Daten werden ergänzt – lade die Seite später neu, um den aktuellen Stand zu sehen
869113-09-7OC(c1ccccc1)(c1ccccc1)C12CC[N+](CCOCc3ccccc3)(CC1)CC2.[Br-]PEJHHXHHNGORMP-UHFFFAOYSA-M869113-09-7DTXSID50235966CHEMBL523299CHEBI:79040Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
BeschreibungUmeclidinium bromide is a long-acting muscarinic acetylcholine antagonist developed by GlaxoSmithKline and approved by the US FDA at the end of 2013 for use in combination with vilanterol, a b2 agonist, for the treatment of chronic obstructive pulmonary disease. Due to umeclidinium’s poor oral bioavailability, the drug is administrated by inhalation as dry powder.
VerwendenUmeclidinium Bromide is considered as a potentially long-acting antimuscarinic agent.
DefinitionChEBI: A quaternary ammonium salt that is the bromide salt of umeclidinium. Used in combination with vilanterol for long-term maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease.
Wird geladen…
Wird geladen…
Wird geladen…